PurposeSeveral biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC), and CD8 cells in melanoma. We sought to examine the relationship between these distinct variables with response to PD-1 blockade and long-term benefit.Experimental designWe assessed the association between baseline tumor characteristics (TMB, PD-L1, CD4, and CD8) and clinical features and outcome in 38 patients with advanced NSCLC treated with pembrolizumab (median follow-up of 4.5 years, range 3.8-5.5 years).ResultsPD-L1 expression and CD8 infiltration correlated with each other and each significantly associated with objective response rate (ORR) and progression...
BACKGROUND/AIM:mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatmen...
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as nivolumab and...
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that h...
Pembrolizumab has been approved as first‐line treatment for advanced Non‐small cell lung cancer (NSC...
Anti-programmed death (ligand)-1 [anti-PD-(L)1] therapies such as pembrolizumab, nivolumab or atezol...
Importance: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immun...
Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the tre...
Background Programmed cell death ligand 1 (PD-L1) expressed on tumor and immune cells are both assoc...
Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-...
BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1)...
The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression ...
Despite advances made during the last two decades, lung cancer remains the leading cause of cancer-r...
AbstractBACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1...
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade ...
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade ...
BACKGROUND/AIM:mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatmen...
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as nivolumab and...
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that h...
Pembrolizumab has been approved as first‐line treatment for advanced Non‐small cell lung cancer (NSC...
Anti-programmed death (ligand)-1 [anti-PD-(L)1] therapies such as pembrolizumab, nivolumab or atezol...
Importance: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immun...
Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the tre...
Background Programmed cell death ligand 1 (PD-L1) expressed on tumor and immune cells are both assoc...
Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-...
BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1)...
The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression ...
Despite advances made during the last two decades, lung cancer remains the leading cause of cancer-r...
AbstractBACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1...
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade ...
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade ...
BACKGROUND/AIM:mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatmen...
Immunotherapy with monoclonal antibodies against programmed cell death (PD-1), such as nivolumab and...
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that h...